Nov 13 2023Cleveland Clinic
In the trial, for patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly injections of semaglutide at a dose of 2.4 mg was superior to placebo in reducing the risk of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke over an average follow-up of 40 months.
More than half the world population is projected to have overweight or obesity by the year 2035. High body-mass index is estimated to have accounted for 4 million deaths globally in 2015, more than two thirds of which were caused by cardiovascular diseases. Related StoriesIn addition to taking either semaglutide or placebo for the trial, all participants also received standard-of-care treatment for cardiovascular disease, such as cholesterol-modifying medications, antiplatelet therapies, beta blockers or other treatments.